Abstract 1806P
Background
The randomized, double-blind, phase 3 MAGNITUDE study evaluated NIRA+AAP vs placebo and AAP (PBO+AAP) as 1st line therapy for mCRPC that was HRR+ based on targeted next-generation sequencing of tumor tissue and/or plasma-based assays.1 Here we aimed to assess treatment efficacy by assay.
Methods
Tumor tissue and/or plasma was collected from mCRPC patients (pts) who consented to the pre-screening protocol and tested using local tissue assays or centrally using the Foundation Medicine FoundationOne®CDx (F1CDX®) tissue assay or Agilent-Resolution Bioscience Resolution HRD™ Plasma assay. Pts HRR+ (BRCA1, BRCA2, FANCA, PALB2, CHEK2, BRIP1, HDAC2, ATM, CDK12) were randomized 1:1 to receive NIRA+AAP or PBO+AAP (NCT03748641). Primary (radiographic progression-free survival, rPFS) and secondary end-points (time to cytotoxic chemotherapy, TCC; time to symptomatic progression, TSP; and overall survival, OS) are reported for interim analysis 2 for each subgroup (events [NIRA+AAP/PBO+AAP], Hazard ratio and 95% CI).
Results
Overall, 423 pts were HRR+ with 225 BRCA+. Pts, 159 (96), were HRR+ (BRCA+) with both assays, the remaining pts were positive with either tissue/plasma (Table). Pts, 124 (62) HRR+ (BRCA+), were tissue positive but plasma negative, and 38 (17) HRR+ (BRCA+) pts were positive with plasma, but tissue negative. Hazard ratios for end-points, except OS, had p<0.05 for pts BRCA positive by either assay, with similar results for HRR+ pts.
Table: 1806P
Population, n (NIRA+APP / PBO+APP) | rPFS | TCC | TSP | OS | |
BRCA+ | Overall 113/112 | 57/78 0.55 (0.39-0.78) | 28/44 0.56 (0.35-0.90) | 31/51 0.54 (0.35-0.85) | 43/49 0.88 (0.58-1.34) |
Plasma 71/79 | 0.63 (0.42-0.96) | 0.49 (0.28-0.87) | 0.51 (0.30-0.89) | 0.88 (0.53-1.46) | |
Tissue 76/86 | 0.51 (0.33-0.77) | 0.44 (0.24-0.82) | 0.50 (0.28-0.89) | 0.83 (0.49-1.40) | |
All HRR | Overall 212/211 | 124/140 0.76 (0.60-0.97) | 57/77 0.67 (0.47-0.94) | 54/83 0.60 (0.42, 0.84) | 90/89 1.01 (0.75-1.36) |
Plasma 129/148 | 0.77 (0.57-1.04) | 0.60 (0.39-0.92) | 0.58 (0.38-0.88) | 1.04 (0.73-1.49) | |
Tissue 144/147 | 0.80 (0.59-1.08) | 0.62 (0.40-0.96) | 0.56 (0.36-0.86) | 0.97 (0.67-1.42) |
Conclusions
Clinically meaningful benefit from NIRA+AAP are similar for BRCA+ pts detected by either tissue or plasma-based assays. Positivity by either test is sufficient to guide treatment decisions. 1. Efstathiou E, et al. J Clin Oncol. 2023;41(suppl 6):170.
Clinical trial identification
NCT03748641.
Editorial acknowledgement
Legal entity responsible for the study
Janssen Research & Development, LLC.
Funding
Janssen Research & Development, LLC.
Disclosure
G. Attard: Financial Interests, Personal, Invited Speaker: Janssen, Astellas, AstraZeneca; Financial Interests, Personal, Advisory Board: Janssen, Astellas, Novartis, Bayer, AstraZeneca, Pfizer, Sanofi, Sapience, Orion, Novartis; Financial Interests, Personal, Royalties, Included in list of rewards to discoverers of abiraterone: Institute of Cancer Research; Financial Interests, Institutional, Invited Speaker: Artera, Veracyte, Janssen, Novartis, Pfizer; Financial Interests, Institutional, Research Grant: Janssen, Astellas, Novartis; Non-Financial Interests, Principal Investigator: Janssen, Astellas; Non-Financial Interests, Advisory Role: Janssen, AstraZeneca; Non-Financial Interests, Project Lead: Artera, Veracyte. S.K. Sandhu: Financial Interests, Institutional, Advisory Board, I have served on advisory boards for BMS. The contracts for my role are set up with the institution and the funds go to a research fund at Peter MacCallum Cancer Centre: BMS; Financial Interests, Institutional, Advisory Board, I have served on advisory boards for MSD. The e contracts for my role are set up with the institution and the funds go to a research fund at Peter MacCallum Cancer Centre: Merck Sharp and Dohme; Financial Interests, Institutional, Advisory Board, I have served on advisory boards for AstraZeneca. The contracts for my role as an advisor are set up with the institution and the funds go to a research fund at Peter MacCallum Cancer Centre: AstraZeneca; Financial Interests, Institutional, Advisory Board, I have served on advisory boards for Novartis. The contracts for my role as an advisor are set up with the institution and the funds go to a research fund at Peter MacCallum Cancer Centre: Novartis; Financial Interests, Institutional, Advisory Board, I have served on an advisory board for Merck Serono. The contracts for my service are set up with the institution and funds go into a research fund at the Peter MacCallum Cancer Centre: Merck Serono; Financial Interests, Institutional, Research Grant, My institution receives grant funding to run an investigator initiated trial that I lead: Novartis, Genentech, Amgen, AstraZeneca, Merck Serono, Merck Sharp and Dohme; Financial Interests, Institutional, Funding, Pfizer are providing funding to my institution for the conduct of an investigator initiated clinical trial: Pfizer; Non-Financial Interests, Principal Investigator, I am a principal investigator on several of Janssen sponsored studies and don't receive any renumeration for this: Janssen; Non-Financial Interests, Principal Investigator, I am a principal investigator on several Novartis sponsored studies and don’t receive any renumeration for this: Novartis; Non-Financial Interests, Principal Investigator, I am a principal investigator on several of Genentech sponsored studies and don't receive any renumeration for this: Genentech; Non-Financial Interests, Principal Investigator, I am a principal investigator on several of BMS sponsored studies and don't receive any renumeration for this: BMS; Non-Financial Interests, Other, I serve on the Independent Safety and Data Monitoring committee for 2 of Novartis sponsored studies and don’t receive any compensation for this: Novartis; Non-Financial Interests, Principal Investigator, I am the Principal Investigator for several AstraZeneca sponsored studies and am not remunerated for this: AstraZeneca; Non-Financial Interests, Other, I serve on the steering committee for several Janssen sponsored trials and i do not receive compensation for this: Janssen; Non-Financial Interests, Other, I serve on the steering committee for one AstraZeneca sponsored trial and I do not receive compensation for this: AstraZeneca; Non-Financial Interests, Other, I serve on the steering committee for one Genentech sponsored trials and I do not receive compensation for this: Genentech; Non-Financial Interests, Other, I serve on the steering committee for a BMS sponsored trial and I do not receive renumeration for this: BMS. D. Rathkopf: Financial Interests, Trial Chair: Janssen; Financial Interests, Steering Committee Member: Janssen, Genentech; Financial Interests, Institutional, Research Grant, Clinical Trial Grant: Genentech; Non-Financial Interests, Advisory Role: Janssen, Genentech, AstraZeneca, Myovant, Bayer, BMS; Non-Financial Interests, Principal Investigator: Janssen, Genentech, Promontory, Celgene/BMS. E. Castro: Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, Janssen, MSD, Bayer, Pfizer; Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Janssen, Clovis, Pfizer; Financial Interests, Personal, Writing Engagement: Pfizer; Financial Interests, Institutional, Funding: AstraZeneca, Pfizer; Financial Interests, Institutional, Research Grant: Janssen, Bayer; Financial Interests, Institutional, Local PI: Janssen, Pfizer. M. Saad: Financial Interests, Speaker, Consultant, Advisor: AstraZeneca, BMS, Janssen, Merck, MSD, Novartis, Viatris; Financial Interests, Research Funding: Janssen, MSD; Financial Interests, Other, Honoraria: Amgen, Astellas, Cipla, Eisai, Ipsen, Pfizer. M.R. Smith: Financial Interests, Speaker, Consultant, Advisor: Amgen, Astellas, Bayer, Janssen, Lilly, Novartis, Pfizer; Financial Interests, Institutional, Research Funding: Bayer, ESSA, Janssen, Lilly, ORIC. E.J.J. Small: Financial Interests, Speaker, Consultant, Advisor: Fortis, Janssen, Teon Therapeutics; Financial Interests, Stocks/Shares: Fortis, Harpoon Therapeutics, Teon Therapeutics. D. Olmos: Financial Interests, Institutional, Advisory Role: AstraZeneca, Bayer, Janssen; Financial Interests, Speaker, Consultant, Advisor: Bayer, Clovis, Daiichi Sankyo, Janssen, MSD; Financial Interests, Institutional, Research Funding: Astellas, AstraZeneca, Bayer, Genentech/Roche, Janssen, MSD, Pfizer, Tokai. A.J.P.D.S. Gomes: Financial Interests, Speaker’s Bureau: Astellas, Bayer, Janssen; Financial Interests, Research Funding: AstraZeneca, Bayer, Janssen, MSD, Roche; Financial Interests, Advisory Role: Janssen; Financial Interests, Other, Honoraria: Astellas, AstraZeneca, Bayer, Janssen. G. Roubaud: Financial Interests, Speaker, Consultant, Advisor: Astellas, Janssen, MSD, Pfizer; Financial Interests, Research Funding: Bayer. B. Zurawski: Financial Interests, Speaker, Consultant, Advisor: Astellas, Roche; Financial Interests, Funding: BMS, GSK, Janssen, MSD, Merck Serono, Novartis, Roche. E. Efstathiou: Financial Interests, Speaker, Consultant, Advisor: Astellas, AstraZeneca, MSD, Myovant, Pfizer, Sanofi; Financial Interests, Research Funding: Astellas, AstraZeneca, MSD, Myovant, Pfizer, Sanofi. D. Wu, B. Diorio, K. Urtishak, U. Singh, Y. Xu, A. Lopez-Gitlitz, A. del Corral: Financial Interests, Full or part-time Employment: Janssen; Financial Interests, Stocks/Shares: Janssen. K.N.N. Chi: Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Janssen, Point Biopharma, Roche; Financial Interests, Personal, Advisory Board: AstraZeneca, AstraZeneca, Janssen, Merck, Novartis, Pfizer, Point Biopharma, Roche, BMS; Financial Interests, Institutional, Steering Committee Member: AstraZeneca, Janssen, Novartis, Roche; Financial Interests, Institutional, Trial Chair: AstraZeneca, Arvinas, Janssen, Novartis; Financial Interests, Institutional, Local PI: Arvinas.
Resources from the same session
1250P - Assessing lung carcinoma: A retrospective study on volume evaluation, consolidation and infiltration using chest OMX
Presenter: Swarnambiga Ayyachamy
Session: Poster session 14
1251P - Development of a deep learning algorithm for lung cancer diagnosis using methylation and fragment size profiles of cfDNA
Presenter: Jiyoung Huh
Session: Poster session 14
1252P - Quantitative cell signaling activity profiling of solid tumors to support personalized treatment in the FINPROVE basket trial: Presentation of skin tumor data
Presenter: Diederick Keizer
Session: Poster session 14
1253P - Analytic validation and implementation of OncoDEEP: A pan-cancer comprehensive genomic profiling NGS assay for assessing homologous recombination deficiency (HRD)
Presenter: Marcel Trautmann
Session: Poster session 14
1254P - Retrospective analysis of brain OMX: Diagnostic tool for structural (T1) and functional connectome (RS-FMRI) analysis of brain
Presenter: Swarnambiga Ayyachamy
Session: Poster session 14
1255P - Evaluating GPT-4 as an academic support tool for clinicians: A comparative analysis of case records from the literature
Presenter: Marcos Aurelio Fonseca Magalhaes Filho
Session: Poster session 14
1256P - Value of detection of peripheral blood circRNA based on digital PCR in the diagnosis of lung adenocarcinoma
Presenter: Jihong Zhou
Session: Poster session 14
1257P - Double heterozygous prevalence in hereditary cancer syndromes in Northern Mexico population
Presenter: Carlos Burciaga Flores
Session: Poster session 14
1258P - Does FDG PET-based radiomics have an added value for prediction of overall survival in non-small cell lung cancer?
Presenter: Andrea Ciarmiello
Session: Poster session 14
1260TiP - Enhancing lung nodule discrimination with a novel cfDNA test: The cancer signature ensemble (CSE) approach
Presenter: Young-Chul Kim
Session: Poster session 14